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Summary. Aims: To determine the economic benefit of
losartan versus atenolol in patients with essential hy-
pertension from the perspective of the Swiss healthcare
system.
Methods and results: The cost-effectiveness of losar-
tan versus atenolol in the treatment of hypertension was
analyzed by applying the results of the LIFE study to
the Swiss healthcare system using a decision analysis
framework.
The cost-effectiveness shows the losartan cohort to pro-
vide an additional life expectancy of 0.05 years per patient
compared to the atenolol cohort, over a mean follow-up pe-
riod of 4.8 years. Losartan therapy in hypertensive patients
produced net cost savings of CHF 24 per patient and per
4.8 years compared to atenolol from the perspective of the
Swiss health care system. This result was robust after vary-
ing costs of medication, stroke, myocardial infarction and
life expectancy.
Conclusion: The use of a losartan-based regimen in
hypertensive patients with left ventricular hypertrophy in
Switzerland is net cost-saving compared with a atenolol-
based regimen.
Key Words. cost-effectiveness, medical economics, hyper-
tension, stroke losartan, atenolol, LIFE
Background
Stroke is the second most common cause of mortality,
after cardiovascular disease. The annual overall inci-
dence of stroke is estimated at 127’000 in Germany,
112’000 in Italy, 101’000 in UK, 89’000 in Spain and
78’000 in France. Death related to stroke is declining in
many countries (Finland, Sweden, France, Spain) and
in both sexes. The incidence in Switzerland has been
reported to be in the magnitude of 150/100’000/year
[1].
In middle and late adult life, hypertension is un-
doubtedly the strongest modifiable risk factor for both
ischemic and hemorrhagic stroke. Hypertension is
present in approximately 70% of stroke cases. The
risk of stroke rises in proportion to blood pressure, for
males as well as for females, and almost doubles for
every 7.5 mm Hg increment in diastolic blood pressure
(DBP) [2].
Losartan (Cosaar©R) represents one of the newer
classes of antihypertensive agents with potential anal-
ogous efficacy based on evidence of reduction in cardio-
vascular events with ACE inhibitors and further, the
evidence for a possibly greater effect in reduction in
hypertensive left ventricular hypertrophy by ACE in-
hibitors than some other class of agents. Clinical studies
have demonstrated that the frequency of side-effects
in patients receiving losartan alone or in combination
with hydrochlorothiazide (HCTZ) is similar to placebo
[3,4].
The Losartan Intervention For Endpoint reduction
(LIFE) in Hypertension study was undertaken to de-
termine whether losartan could be demonstrated to
be more effective than a member of the betablocker
class in decreasing morbidity and mortality in a rel-
atively high risk hypertensive group [14]. It was
a double-blind, randomized, parallel-group trial in
9’193 hypertensive patients with electrocardiographic
(ECG) evidence for with a mean 4.8 year follow-up
in LIFE to determine whether there was a differ-
ence in primary cardiovascular events between an an-
giotensin II receptor blocker (losartan) [Cosaar©R], and
a betablocker (atenolol) [Tenormin©R and several other
generic brands]. A substudy evaluated these differ-
ences in diabetics. With a similar reduction in blood
pressure, primary events (cardiovascular morbidity
and death) occurred in fewer participants in the losar-
tan group (23.8/1’000 patient-years) than the atenolol
group (27.9/1’000 patient-years) (adjusted hazard ra-
tio: 0.87; 95% CI: 0.77–0.98). Similar results were found
in the diabetic substudy with 39.2/1’000 patient-years
in the losartan group versus 53.6/1’000 patient-years
in the atenolol group (adjusted hazard ratio: 0.76; 95%
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CI: 0.58–0.98). The stroke reduction drove the primary
endpoint difference. There was a highly significant 25%
reduction in the incidence of fatal/nonfatal stroke in the
losartan-treated patients (adjusted hazard ratio 0.75;
95% CI: 0·63–0·89).
The results of the main study indicated a signif-
icant benefit in the losartan group [14]. Event-free
survival was reported in 85.5% of the losartan group
(35.6/1000 patient-years) and 83.6% (31.4/1’000 patient-
years) of the atenolol group (p= 0.04) [5]. Blood pres-
sure, initially 174/98 mm Hg in both groups, was com-
parably reduced (144/81 mm Hg and 145/81 mm Hg
at last visit). Analysis for components of the pri-
mary endpoint showed a benefit for losartan mainly
for stroke but no significant difference in myocar-
dial infarction. The losartan group had an 11% re-
duction in cardiovascular mortality but this reduc-
tion was not statistically significant (adjusted hazard
ratio 0.89; 95% CI: 0.73–1.07). The overall drop-out
rates were 2.2% for Losartan treated patients and
2.0% for atenolol patients. Adverse events causing
dropout from the study were more common in the
atenolol group (18% vs. 13%). This difference was sta-
tistically significant (p< 0.0001). New onset diabetes
developed in 6% of the losartan group vs. 8% of the
atenolol group (adjusted hazard ratio 0.75; 95% CI:
0.63–0.88).
To use the existing resources optimally, the cost-
effectiveness of the different treatment methods must
be known and taken into consideration. Defining and
measuring the cost-effectiveness of a treatment is dif-
ficult. The instruments of evaluation research (e.g.
benefit-risk analysis, cost-effectiveness analysis) must
be used for the evaluation of the efficiency of medical
treatments. Assuming that the outputs of such analyses
are the same (e.g. costs per life-year saved), one then
has the ability to compare different treatments with
each other.
Despite recent guidelines emphasising the need
for aggressive treatment in patients with elevated
blood pressure, the control of hypertension in Europe
and the USA is poor, imposing a considerable bur-
den in terms of patient morbidity and mortality, and
associated healthcare costs. The cost-effectiveness of
losartan in the treatment of patients with diabetic
nephropathy has already been demonstrated by San-
doz et al. based on a Swiss model [6]. As atenolol
is among the most widely prescribed antihyperten-
sives (326’000 annual prescriptions for atenolol among
a total of 700’000 for betablockers and 4 mio. for all
antihypertensives) in Switzerland, a comparison with
Losartan is appropriate and hence essential for policy
making.
Study Objective
The purpose of the following study is to answer the en-
suing question: How cost-effective is losartan versus
atenolol in 60 year old patients with essential hyper-
tension from the perspective of the Swiss healthcare
system?
Methods
Study design
Cost-effectiveness analysis was chosen for the pur-
pose of this study. In contrast to cost-benefit analysis,
non-monetary parameters e.g. the number of life-years
saved are included in the economic assessment as ben-
efit or output criteria. This ensures that the economic
efficiency of a treatment is evaluated with due consid-
eration to the medical success.
The present analysis is retrospective. The results of
the already published double-blind, randomised, con-
trolled clinical trial LIFE (Losartan Intervention for
Endpoint reduction in Hypertension) (Table 1). This
trial was conducted in six European countries and the
US and was used as the basis of efficiency assessment
[7]. It was assumed that the effects on clinical outcomes
can be transferred to Switzerland.
A brief comparison of the effects on clinical outcomes
of the LIFE study of the losartan and atenolol groups
for some particularly cost-relevant clinical events is
shown in Table 2. A detailed description of study de-
sign has been published elsewhere. A review of the de-
sign of the LIFE trial has been published extensively
[8].
Economic study endpoint
The intended endpoint of this cost-effectiveness analy-
sis of losartan therapy is the incremental cost per life-
year gained in Switzerland expressed in Swiss francs
(CHF).
Determination of costs and effectiveness
Costs. The costs are based on the cost incurred by
the social health insurance providers. Specifically, only
prices that are reimbursed were taken into considera-
tion. For the determination of the total costs of losartan
treated group, three directly attributable cost groups
were included: (1) the medication costs for losartan ac-
cording to the dosage used in the LIFE study, (2) the
acute costs and 2 year follow-up of a myocardial infarc-
tion and (3) the acute and 2 year follow-up costs of a
stroke. Indirect costs (e.g. costs related to loss of work)
and intangible costs (e.g. pain) were not included in this
calculation.
The costs of treatment with losartan were based
on pharmacy prices in Switzerland [9], because mainly
pharmacies are authorized to sell drugs to ambulatory
patients. We calculated mean daily treatment costs on
the basis of the mean daily dosages used in patients
in the intent-to-treat population, i.e. 82 mg/d for losar-
tan and 79 mg/d for atenolol. A patient co-payment of
10% was deducted from the pharmacy price. The total
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Table 1. Design of the LIFE study
Objectives To establish whether selective blocking of angiotensin II improves left ventricular hypertrophy beyond
reducing blood pressure
To establish whether selective blocking of angiotensin II reduces cardiovascular morbidity and mortality
Study design Multicentre, double blind, randomised, placebo-controlled study in 945 centers in Scandinavia, England and the
United States
Inclusion criteria Hypertension: sitting blooding pressure systolic 160–200 mmHg, diastolic 95–115 mmHg
ECG diagnosis of left ventricular hypertrophy (Cornell voltage or Sokolow-Lyon Index)
Age: 55–80 years
Exclusion criteria Secondary hypertension
Myocardial infarction, cerebrovascular insult 6 months prior to study, angina pectoris requiring betablocker
treatment, LV ejection fraction <40%
Intervention 1–2 week placebo run-in phase
Losartan 50 mg/d, titrated to 100 mg/d, if necessary with 12.5 hydrochlorothiazide
Atenolol 50 mg/d, titrated to 100 mg/d, if necessary with 12.5 hydrochlorothiazide
Endpoints Primary: combined endpoint death, myocardial infarction, stroke
Secondary: total mortality, angina pectoris, new onset diabetes, coronary or peripheral vascularisation
Period of observation 4 years
Patients 9’193 patients, average age 66.9 years, 54% women
Losartan group: 4’605 patients, average age 66.9 years, 54% women, history of vascular disease 26%, smokers
16%, diabetes 13%, mean blood pressure 174.3/97.9 mmHg
Atenolol group: 4’588 patients, average age 66.9 years, 54% women, history of vascular disease 24%, smokers
17%, diabetes 13%, mean blood pressure 174.5/97.7 mmHg
Table 2. Comparison of treatment effects in the LIFE study
Losartan Atenolol Adjusted hazard
(Rate/1000/ (Rate/1000/ (ratio (95%
Group year) year) confidence limits)
Primary 23.8 27.9 0.87 (0.77–0.98)
composite
endpoint+
Cardiovascular 9.2 10.6 0.89 (0.73–1.07)
mortality
Stroke 10.8 14.5 0.75 (0.63–0.89)
Myocardial 9.2 8.7 1.07 (0.88–1.31)
infarction
New onset 13.0 17.4 0.75 (0.63–0.88)
diabetes mellitus
+Cardiovascular mortality, stroke, and myocardial infarction.
drug costs were CHF 2.62 million per 1’000 patients,
based on a daily treatment cost of CHF 1.50 for losar-
tan and CHF 0.46 for atenolol and a median treatment
period of 4.8 years. Hydrochlorothiazide and additional
drug costs were not valued, because they did not differ
significantly between the groups.
These total medication costs were projected assum-
ing a patient compliance rate of 100% throughout the
treatment period. As it may be assumed that the ac-
quisition costs for losartan also apply to those study
patients who no longer take the medication and as less
than 9% of patients died during the observation period
the medication costs were calculated for 100% of the
patients (Table 3).
The Swiss-based costs of an acute myocardial infarc-
tion and of a stroke (medication costs, interventions,
Table 3. Costs in the losartan and atenolol groups per 1000
patients over 4.8 years in Swiss Francs
Difference (95%
Group Losartan Atenolol confidence limits)
Medication cost 2’620’397 797’749 1’822’648
with 82 mg/day
losartan and
79 mg/day atenolol
Cost of myocardial 1’579’852 1’505’620 74’232
infarctions (−180’674; 466’742)
Cost of ischemic 5’722’442 7’649’942 −1’927’500
strokes (−2’830’479; −841’494)
Total costs per 9’922’691 9’953’311 −30’620
1’000 patients (−1’188’505; 1’447’896)
Discounted at −24’227
5% per year (−940’356; 1’145’589)
hospitalisation, out-patient treatment, rehabilitation),
have previously been calculated by an international
study group. In this analysis, the direct medical costs of
ischemic strokes and myocardial infarctions were eval-
uated using a decision analysis model, supplemented
with information from local Delphi panels [10]. In brief,
these calculations covered the acute care costs from
a health care system perspective, including follow-up
health care resource utilisation (in- and outpatient) for
24 months after the index hospitalisation.
The acute care costs per patient with stroke resp.
myocardial infarction were CHF 28’305 resp. 24’972.
The corresponding follow-up costs were CHF 85’281
resp. 11’772. These costs were all adjusted to 2003 val-
ues, taking into account inflation.
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In order to determine the treatment costs that could
be avoided by the use of losartan, the avoidable events
per 1’000 patients over three years were taken from
the LIFE study and multiplied by the treatment costs
of each individual treatment and over the study period
of 4.8 years [11]. Only costs were discounted at a base
discount rate of 5% which is the standard rate applied
for health care investments in Switzerland and which is
supported by the recommendations by the Swiss Office
of Social Insurance [12].
Effectiveness. In this economic analysis, the criterion
for effectiveness is represented by the life-years gained
in the group treated with losartan, compared to the
group that received atenolol. Even though the LIFE
trial did not yield a statistically significant reduction
in cardiovascular morbidity (a secondary endpoint), we
projected survival beyond the trial period to incorpo-
rate the full effects of stroke on survival. Estimation
of the average life expectancy of hypertensive patients
was based on the DEALE method [13,14], using the
all-cause mortality of Swiss population analogous to the
LIFE population in terms of age and gender distribu-
tion [15]. In 2000, the average life expectancy of a 60
year old Swiss person was 76.2 years for men and 82.3
years for women [32]. On this basis, the remaining life
expectancy of persons with a mean age of 66.9 years is
therefore 11.8 years. The LIFE study reports a disease-
specific over-mortality in the atenolol group of 0.0847
per patient. This figure is used as the disease-specific
excess mortality. By linking both mortality rates ac-
cording to the DEALE method, the adjusted life ex-
pectancy, can be calculated to be 11.04 years [30,31].
Cost-effectiveness of losartan treatment. The costs per
life-year saved can be calculated by dividing the dis-
counted cost difference between the losartan and the
atenolol group by the number of life-years gained in
the losartan group.
Sensitivity analyses. Sensitivity analyses were per-
formed in order to test the accuracy and sensitivity of
the results (i.e. the costs per life-year saved). For this
purpose and for simplicity only the medication costs for
losartan, the treatment costs for the events observed
and the approximated life expectancy were varied by
±20%. We judge these to be the most important, costly
parameters. Because the discount rate of 5% can vary
too, we calculated the cost-effectiveness for a discount
rate between 3 and 7%.
Results
Table 3 shows the individual costs in the following cost
groups: daily treatment costs, costs of myocardial in-
farction and stroke in the group treated with losartan
and in the atenolol group. It is clear that there is an addi-
tional medication cost of approximately CHF 1’823 per
patient over 4.8 years in the losartan group compared to
the atenolol group. In contrast, a savings potential can
be seen in the losartan group, as the costs of the most
expensive endpoint stroke are reduced. Total costs of
approximately CHF 9’923 can be calculated for a pa-
tient treated with losartan over 4.8 years. Total costs
in a patient treated with atenolol are CHF 9’953. Thus,
the total cost difference in favour of losartan are nom-
inal CHF 31 (95% CI: −1189; 1448), resp. discounted
CHF 24 (95% CI: −940; 1146).
The calculation of effectiveness showed an additional
life expectancy of 0.0495 years in the losartan cohort
in comparison to the atenolol group over a period of
observation of 4.8 years (Table 4).
The primarily intended cost-effectiveness analysis
of losartan treatment made no more sense due to equiv-
alence between the groups. The net savings achieved
Table 4. Expected additional life expectancy due to losartan
therapy
Average age of patients at baseline
in LIFE study
Losartan group 66.9 years
Atenolol group 66.9 years
Normal life expectancy
in Switzerland
Men 76.2 years
Women 82.3 years
Life expectancy study population,
weighted
(Study population: 59% men, 11.8 years
41% women)
Weighted mortality rate 0.0847
per patient year
Expected fatal cases in 32.5/1’000
atenolol group
Disease specific mortality 0.00847
rate per annum
Adjusted mortality
Adjusted average mortality 0.0906
(DEALE)
Remaining life expectancy 11.04 years
(DEALE)
Expected fatal events
Losartan 28.01/1’000 patients
Atenolol 32.50/1’000 patients
Cases prevented 4.48/1’000 patients
Years of Life Saved (YOLS) per
1’000 Patients
(Prevented cases /1’000 Patients × 4.48 × 11.04 = 49.51 years
remaining life expectance of
study population)
Incremental life expectancy of 0.0495 years/patient
losartan treatment in comparison
to atenolol
∗Declining Exponential Approximation of Life Expectancy.
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Fig. 1. Univariate Sensitivity analysis: Effect of variation of key input variables on cost-effectiveness ratio.
with losartan of approximately CHF 31 per patient
yields losartan as an economically dominant option. The
calculation as a ratio of cost per life-year saved hence
makes no sense.
The results of the sensitivity analysis (Fig. 1) con-
firm that the estimated net savings are maintained over
a large range of variation of the input variables. Dis-
Table 5. Cost-effectiveness of selected cardiovascular interventions
Cost per life-year saved
Intervention in Swiss Francs Source
Losartan versus atenolol in hypertension (LIFE Study) <0∗ Present study
Lisinopril in congestive heart failure (ATLAS) <0∗ Ess S et al. [19]
Captopril after myocardial infarction (SAVE) 1’600 Szucs T, Berger K, Schulte-Hillen J,
Kleber FX [20]
Beta-blockers for post-myocardial infarction patients at high risk 3’600 Goldman L, Sia ST, Cook EF,
Rutherford JD, Weinstein MC [21]
Pravastatin therapy for CHD patients with slightly 6’985 Szucs et al. [22]
increased cholesterol values (LIPID)
Pravastatin therapy for CHD patients with increased cholesterol 12’800 Berger K, Klose G, Szucs T [11]
values (PLAC I/II)
Low cholesterol diet for men aged ≥60 years with a cholesterol 14’480 Taylor WC, Pass TM,
value of 180 mg/dl (4.7 mmol/l) Shepard DS, Komaroff AL [23]
Amlodipine therapy for CHD patients with normal cholesterol 14’650 Cathomas G, Erne P, Szucs TD [24]
(PREVENT)
Pravastatin therapy for CHD patients over 60 years with normal 18’400 Berger K, Klose G, Szucs TD [11]
cholesterol values (CARE)
Antihypertensive agents for patients aged ≥40 years with diastolic 19’280 Stason WB, Weinstein MC [25]
blood pressure levels ≥105 mm Hg
Beta-blockers for post-myocardial patients at low risk 20’400 Goldman L, Sia ST, Cook EF,
Rutherford JD, Weinstein MC [26]
Hypertensive patients with multiple risk factors (ASCOT) 20’003 Szucs TD, Muller D, Darioli R. [26]
Clopidogrel in coronary secondary prevention (CAPRIE) 24’705 Haldemann R et R et al. [27]
tPA for myocardial infarction (GUSTO IV) 39’440 Mark DB, Hlatky SB, Davis CE [28]
∗Values <0 denotes net savings, i.e. a dominant economic strategy.
counting at 3% resp. 7% revealed a cost difference in
favour of losartan of CHF 27 (95% CI:−1031; 1256) resp.
CHF 22 (95% CI: −859; 1046). In the worst case, a the-
oretical cost-effectiveness ratio would be CHF 25336
per lifeyear gained, which would still be considered a
worthwhile health care investment. Table 5 displays the
cost-effectiveness of selected health care interventions.
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Discussion
Using the example of Losartan, the economic assess-
ment of angiotensin II antagonists in hypertensive pa-
tients with LVH has shown that the administration
of this medication is a highly economically viable op-
tion with net savings. The benefits of Losartan are at-
tributed almost exclusively to the prevention of stroke.
However, the economic performance of a medical in-
tervention can never be judged in isolation, but must
always be seen in comparison to other interventions
and should be discussed in relation to this background.
The positioning of the results in the context of the cost-
effectiveness of other interventions is shown in Table 5,
and makes it clear that treatment with losartan is in a
more favourable range, than can be attained by some
other broadly accepted interventions.
To the best of our knowledge, the current article
is the first published economic analysis based on the
LIFE study. As this is a retrospective analysis, and
benefits were not directly recorded, it was not possi-
ble to carry out a cost-utility analysis. Such an analysis
specifies costs in monetary units and consequences as
benefit, i.e. as a quantity that reflects the preferences
of the affected target group for a state of health (e.g.
quality-adjusted life-years).
A limitation of the present analysis is certainly that
the results of the LIFE study, that was conducted in
the USA, the United Kingdom and Scandinavia were
transferred to the situation in Switzerland, and that the
estimated life expectancy of CHD patients in Switzer-
land was used for the calculation of cost-effectiveness.
There are indications that the influence of other risk
factors may possibly vary in the degree of severity to
which they affect the Swiss population compared with
the original study population. For this reason, the esti-
mated life expectancy was also varied in the sensitivity
analyses. On the other hand, the patient population of
the LIFE study is comparable to a Swiss hypertension
population with respect to age, co-morbidity and con-
comitant medication [16]. It should also be pointed out
that patients in the LIFE study are only partly repre-
sentative of the total collective of hypertensive patients
in Switzerland: as always, study patients are naturally
carefully selected in terms of co-morbidity, compliance
and quality of care. In this respect, the results of the
LIFE study correspond to the best case scenario. Fur-
thermore, LIFE did not differentiate individually be-
tween non-fatal and fatal events, as this endpoint was
defined, recorded and analysed as a combined endpoint
in the LIFE study.
We believe that the LIFE trial represents an im-
portant body of evidence requiring a health economic
assessment. Even though the impact of Losartan on
the endpoint myocardial infarction was not significant,
the endpoint stroke represents an extremely expen-
sive endpoint for the Swiss health care system. Ad-
ditional analyses of the LIFE trial further emphasize
the benefit of losartan compared with atenolol, in mod-
erately hypertensive patients without overt vascular
disease, demonstrating that the benefit of losartan in
this population is independent of the drug’s blood pres-
sure lowering effect. Devereux et al. have now shown
even greater reductions in both the composite endpoint
and the components of the primary endpoint for losar-
tan compared with atenolol in patients who had no overt
vascular disease and which were therefore at lower risk
[17].
At this point it should again be stressed that the
present calculation model for Switzerland follows an
extremely conservative approach. Potential savings in
the avoidance of intensive care, loss of working time
or rehabilitation measures can only be surmised but
not quantified and evaluated. In the losartan stud-
ies that have been carried out to date, no data has
been given with respect to differences in the pa-
tients’ quality of life, differences concerning neces-
sary rehabilitation measures and the variable num-
ber of early retirements and lost working days in the
losartan and atenolol groups. As it may be assumed
that these costs are not inconsiderable in amount,
further potential savings could be exploited by us-
ing more effective and efficient therapeutic strate-
gies. Moreover, the low incidence of side effects with
losartan in comparison to other drugs that are effec-
tive in secondary prevention was not included in the
calculations.
Another reason, why our estimates are likely to un-
derestimate the true economic value of losartan is that
we did not value the benefits of losartan in reducing the
new onset of diabetes. Our group has determined that
the mean annual per patient costs of type 2 diabetics in
Switzerland are approximately CHF 3’500 [18]. These
avoidable costs may thus be factored into the overall
equation and may contribute favourably to the numer-
ator of the cost-effectiveness ratio of the present study.
This clinical benefit is extremely important also from a
public health perspective.
It also has to be considered that our cost analysis is
a “within trial” analysis, that is, costs are limited to the
study duration of the LIFE trial. Only a 2-year follow-
up of the costs of the first index event was used to take
into account possible sequelae, e.g. rehospitalisations.
As a result, potential costs and benefits that occur af-
ter more than the mean follow-up of 4.8 years are not
included in the calculations.
A further limitation of this study is the assumption
of a 100% compliance of drug treatment and the omit-
ting of hydrochlorothiazide costing. As we did not have
access to the raw data set, we were not able to deter-
mine the economic impact in a pragmatic sense without
serious modelling. However, given the metabolic side-
effect profile of hydrochlorothiazide, the costs of new-
onset diabetes will likely reverse the economics of this
non-expensive drug class.
Economic evaluations are of practical relevance for
the general practitioner to the extent that the conscious
use of economical medical therapies reduces their fear
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and uncertainty about budget adherence and recourse,
and justifies his prescribing practice. In addition, the
use of efficient medical therapies offers the individual
doctor some relief for their medicines budget, e.g. by
reducing the prescriptions of concomitant medications,
and a greater individual manoeuvrability within the
framework of the fixed prescription budget allocated
to them.
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